Severe and steroid-resistant Crohn's disease.

Détails

ID Serval
serval:BIB_0D992FC757A2
Type
Article: article d'un périodique ou d'un magazine.
Sous-type
Synthèse (review): revue aussi complète que possible des connaissances sur un sujet, rédigée à partir de l'analyse exhaustive des travaux publiés.
Collection
Publications
Institution
Titre
Severe and steroid-resistant Crohn's disease.
Périodique
Digestion
Auteur(s)
Michetti P., Mottet C., Juillerat P., Felley C., Vader J.P., Burnand B., Gonvers J.J., Froehlich F.
ISSN
0012-2823
Statut éditorial
Publié
Date de publication
2005
Peer-reviewed
Oui
Volume
71
Numéro
1
Pages
19-25
Langue
anglais
Notes
Publication types: Journal Article ; Review - Publication Status: ppublish
Résumé
Patients with moderate to severe disease and patients with steroid-refractory or steroid-dependent disease differ in their management, as the latter groups usually include patients with less acute situations. Systemic corticosteroids represent the mainstay of the management of moderate to severe disease and remain the first-line therapy in this setting. Infliximab is the choice alternative for patients who do not respond to steroids or in whom steroids are contraindicated. Purine analogues, methotrexate and infliximab have shown efficacy in achieving steroid-free remission in patients with steroid-refractory or -dependent disease. Other fast-acting immunosuppressors showed little benefit. Surgery may be indicated in this setting. Nataluzimab may prove useful in patients refractory to infliximab.
Mots-clé
Antibodies, Monoclonal, Crohn Disease, Drug Resistance, Gastrointestinal Agents, Glucocorticoids, Humans, Severity of Illness Index
Pubmed
Web of science
Création de la notice
25/01/2008 16:58
Dernière modification de la notice
20/08/2019 13:34
Données d'usage